

**REGIONS INCLUDED:**

Avera McKennan | Avera Queen of Peace | Avera St. Luke's | Avera Sacred Heart | Avera Marshall

## NON-SMALL CELL LUNG CANCERS (NSCLC)

### AN IN-DEPTH REVIEW OF NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) GUIDELINES

- Initial/Diagnostic Evaluation
  - Pathology review
  - H&P
  - CT chest
  - CBC, platelets, chemistry profile
- Testing based on histologic subtype (Adenocarcinoma or Squamous Cell Carcinoma)
  - Molecular testing to identify driver mutations to guide treatment
    - When appropriate, perform EGFR, ALK, ROS1, or BRAF testing
    - When appropriate, perform PD-L1 testing
- Treatment given based on initial evaluation and molecular testing
  - Radiation considered and/or given for localized (in the lung/bronchus) symptoms
  - Radiation considered and/or given for metastatic disease to the brain if present
  - Radiation considered and/or given for metastatic disease to bone if present
  - Appropriate systemic treatment based on molecular testing results

### PATIENTS EVALUATED:

- Non-Small Cell Lung Cancers (NSCLC): Adenocarcinoma and Squamous Cell Lung Cancer histologies only.
- Clinical Stage IV patients with distant metastatic disease only.
- Patients initially evaluated for NSCLC at an ACI facility in 2017 (N=74)

### RESULTS:

**100%** : Initial/diagnostic evaluation  
meets NCCN guidelines.

**100%** : First course of treatment concordant  
per NCCN guidelines.

- 100 percent of eligible patients were considered for and/or received molecular testing when appropriate.
- 100 percent of eligible patients were considered for and/or received radiation therapy for local symptoms, bone metastatic disease or brain metastatic disease.
- 100 percent of eligible patients were considered for and/or received systemic treatment based on molecular testing.